CY1118893T1 - Μεθοδοι ταυτοποιησης αντισωματων με μειωμενη ανοσογονικοτητα - Google Patents

Μεθοδοι ταυτοποιησης αντισωματων με μειωμενη ανοσογονικοτητα

Info

Publication number
CY1118893T1
CY1118893T1 CY20171100428T CY171100428T CY1118893T1 CY 1118893 T1 CY1118893 T1 CY 1118893T1 CY 20171100428 T CY20171100428 T CY 20171100428T CY 171100428 T CY171100428 T CY 171100428T CY 1118893 T1 CY1118893 T1 CY 1118893T1
Authority
CY
Cyprus
Prior art keywords
methods
identifying antibodies
reduced immunity
identifying
tnf
Prior art date
Application number
CY20171100428T
Other languages
English (en)
Inventor
Fiona A Harding
Olivia Jennifer Razo
Original Assignee
Abbvie Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of CY1118893T1 publication Critical patent/CY1118893T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Η γνωστοποίηση περιγράφει μεθόδους ταυτοποίησης παραλλαγής αντισώματος αναφοράς με μειωμένη ανοσογονικότητα συγκριτικά με το αντίσωμα αναφοράς. Η γνωστοποίηση περιγράφει επιπλέον παραλλαγές αντισώματος αναφοράς αντι-TNF-α που έχει μειωμένη ανοσογονικότητα συγκριτικά με το αντίσωμα αναφοράς αντι-TNF-α.
CY20171100428T 2012-09-19 2017-04-11 Μεθοδοι ταυτοποιησης αντισωματων με μειωμενη ανοσογονικοτητα CY1118893T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261703170P 2012-09-19 2012-09-19
PCT/US2013/060480 WO2014047222A2 (en) 2012-09-19 2013-09-18 Methods for identifying antibodies with reduced immunogenicity

Publications (1)

Publication Number Publication Date
CY1118893T1 true CY1118893T1 (el) 2018-01-10

Family

ID=49304336

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100428T CY1118893T1 (el) 2012-09-19 2017-04-11 Μεθοδοι ταυτοποιησης αντισωματων με μειωμενη ανοσογονικοτητα

Country Status (27)

Country Link
US (1) US9279016B2 (el)
EP (2) EP3211006A3 (el)
JP (1) JP2015537190A (el)
KR (1) KR20150056788A (el)
CN (1) CN104704000A (el)
AU (1) AU2013318147B2 (el)
BR (1) BR112015005857A2 (el)
CA (1) CA2885422A1 (el)
CY (1) CY1118893T1 (el)
DK (1) DK2897978T3 (el)
ES (1) ES2621285T3 (el)
HK (1) HK1211306A1 (el)
HR (1) HRP20170937T1 (el)
HU (1) HUE032569T2 (el)
IL (1) IL237833A0 (el)
IN (1) IN2015DN01967A (el)
LT (1) LT2897978T (el)
MX (1) MX2015003541A (el)
NZ (1) NZ705606A (el)
PL (1) PL2897978T3 (el)
PT (1) PT2897978T (el)
RS (1) RS56093B1 (el)
RU (1) RU2648141C2 (el)
SG (1) SG11201502094TA (el)
SI (1) SI2897978T1 (el)
TW (1) TWI519646B (el)
WO (1) WO2014047222A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478802B (zh) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α蛋白B细胞表位，含此表位的多抗原肽及应用
JP7473339B2 (ja) * 2017-03-07 2024-04-23 エフ． ホフマン－ラ ロシュ アーゲー 代替の抗原特異的抗体変異体を発見するための方法
WO2020128863A1 (en) * 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
WO2021005607A1 (en) * 2019-07-09 2021-01-14 National Institute For Biotechnology In The Negev Ltd. Antibodies with reduced immunogenicity
WO2021064009A1 (en) 2019-09-30 2021-04-08 Scirhom Gmbh Protein binders to irhom2 epitopes
FR3104582A1 (fr) * 2019-12-17 2021-06-18 Commissariat A L'energie Atomique Et Aux Energies Alternatives Variants de l’adalimumab au potentiel immunogène réduit
CN113125714B (zh) * 2019-12-31 2023-06-16 科美博阳诊断技术(上海)有限公司 一种人类免疫缺陷病毒抗体检测试剂盒及其应用
WO2021147642A1 (en) * 2020-01-20 2021-07-29 Bio-Thera Solutions, Ltd. Methods, models and systems related to antibody immunogenicity
KR102568430B1 (ko) * 2020-11-16 2023-08-24 바디텍메드(주) 항 약물 항체의 신속 검출 방법
KR20230150319A (ko) 2021-03-01 2023-10-30 사이롬 게임베하 iRhom2에 대한 인간화 항체
WO2022207652A1 (en) 2021-03-29 2022-10-06 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
WO2024033362A1 (en) 2022-08-08 2024-02-15 Atb Therapeutics Humanized antibodies against cd79b

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
EP0189330B1 (en) 1985-01-25 1992-12-02 The Kitasato Institute Antitumor antibiotics and their production
US5264357A (en) 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
NZ512006A (en) * 1996-02-09 2005-05-27 Abbott Biotech Ltd Medical treatment with human TNF-alpha antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
AR021833A1 (es) 1998-09-30 2002-08-07 Applied Research Systems Metodos de amplificacion y secuenciacion de acido nucleico
AU1728800A (en) 1998-11-18 2000-06-05 Genentech Inc. Antibody variants with higher binding affinity compared to parent antibodies
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
AU7537200A (en) 1999-09-29 2001-04-30 Solexa Ltd. Polynucleotide sequencing
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
UA81743C2 (uk) * 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
WO2002027029A2 (en) 2000-09-27 2002-04-04 Lynx Therapeutics, Inc. Method for determining relative abundance of nucleic acid sequences
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6956114B2 (en) 2001-10-30 2005-10-18 '454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
WO2004029284A2 (en) 2002-09-30 2004-04-08 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
BR122018071808B8 (pt) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugado
TWI556829B (zh) * 2004-04-09 2016-11-11 艾伯維生物技術有限責任公司 用於治療ＴＮＦα相關失調症之多重可變劑量療法
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
CA2587766A1 (en) 2004-11-10 2007-03-01 Macrogenics, Inc. Engineering fc antibody regions to confer effector function
ES2340205T3 (es) 2005-11-12 2010-05-31 Eli Lilly And Company Anticuerpos anti-egfr.
WO2009032128A1 (en) * 2007-08-28 2009-03-12 Abbott Biotechnology Ltd. Compositions and methods comprising binding proteins for adalimumab
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
WO2010121140A1 (en) 2009-04-16 2010-10-21 Facet Biotech Corporation ANTI-TNF-α ANTIBODIES AND THEIR USES
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
KR20120138241A (ko) * 2010-03-11 2012-12-24 화이자 인코포레이티드 ｐＨ 의존성 항원 결합을 갖는 항체
RU2584597C2 (ru) * 2010-08-13 2016-05-20 Рош Гликарт Аг Антитела против а2 тенасцина с и способы их применения
KR20130138802A (ko) * 2010-10-20 2013-12-19 옥스포드 바이오테라퓨틱스 리미티드 항체

Also Published As

Publication number Publication date
IN2015DN01967A (el) 2015-08-14
WO2014047222A3 (en) 2014-10-23
HK1211306A1 (en) 2016-05-20
WO2014047222A2 (en) 2014-03-27
CA2885422A1 (en) 2014-03-27
KR20150056788A (ko) 2015-05-27
RU2015111671A (ru) 2016-11-10
BR112015005857A2 (pt) 2017-08-08
EP2897978B1 (en) 2017-03-22
ES2621285T3 (es) 2017-07-03
WO2014047222A9 (en) 2014-06-26
HUE032569T2 (en) 2017-09-28
PT2897978T (pt) 2017-05-22
RS56093B1 (sr) 2017-10-31
NZ705606A (en) 2018-05-25
EP3211006A3 (en) 2017-11-08
EP3211006A2 (en) 2017-08-30
SG11201502094TA (en) 2015-04-29
US9279016B2 (en) 2016-03-08
MX2015003541A (es) 2015-10-26
CN104704000A (zh) 2015-06-10
TWI519646B (zh) 2016-02-01
EP2897978A2 (en) 2015-07-29
LT2897978T (lt) 2017-06-12
US20140227251A1 (en) 2014-08-14
SI2897978T1 (sl) 2017-05-31
TW201418469A (zh) 2014-05-16
PL2897978T3 (pl) 2017-08-31
JP2015537190A (ja) 2015-12-24
HRP20170937T1 (hr) 2017-11-03
RU2648141C2 (ru) 2018-03-22
AU2013318147B2 (en) 2018-01-04
AU2013318147A1 (en) 2015-03-19
IL237833A0 (en) 2015-05-31
DK2897978T3 (en) 2017-05-15

Similar Documents

Publication Publication Date Title
CY1118893T1 (el) Μεθοδοι ταυτοποιησης αντισωματων με μειωμενη ανοσογονικοτητα
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
ECSP17021175A (es) Terapias de combinación con anticuerpos anti-cd38
CL2016000460A1 (es) Proteínas de unión al antígeno gitr
TR201905829T4 (tr) Buzdolabı.
CO7151521A2 (es) Anticuerpos anti-fcrn
UY34456A (es) Anticuerpos anti-il-36r
DK3590962T3 (da) Enkeltdomæneantistoffer rettet mod intracellulære antigener
CY1118885T1 (el) Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης
DK2953976T3 (da) Specifikke modificeringssteder i antistoffer til fremstilling af immunkonjugater
BR112015000530A2 (pt) vacina de antígeno micobacteriano.
DK3736291T5 (da) Anti-FCRH5-antistoffer
BR112016000106A2 (pt) anticorpos c1q do fator anti-complemento e usos dos mesmos
UY34582A (es) Anticuerpos anti-cxcr3
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
DK3164414T3 (da) Antistoffer for IL-15
BR112014026634A2 (pt) direcionador
DK3068800T3 (da) FcRn-specifikke antistoffer
AR097668A1 (es) Colorante-polímero
CO7111295A2 (es) Anticuerpo anti-rob04
DK3065774T3 (da) Anti-CCL17-antistoffer
BR112015025165A2 (pt) veículo
DE112014001377A5 (de) Boosterkupplung
TN2013000364A1 (fr) تصميم جديد لطائرة مدنية ذات مقعد واحد و انظمة سلامة متطورة